Country: United States
Language: English
Source: NLM (National Library of Medicine)
OLMESARTAN MEDOXOMIL (UNII: 6M97XTV3HD) (OLMESARTAN - UNII:8W1IQP3U10)
Bryant Ranch Prepack
OLMESARTAN MEDOXOMIL
OLMESARTAN MEDOXOMIL 20 mg
ORAL
PRESCRIPTION DRUG
Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressu
Benicar is supplied as yellow, round, film-coated, non-scored tablets containing 5 mg of olmesartan medoxomil, as white, round, film-coated, non-scored tablets containing 20 mg of olmesartan medoxomil, and as white, oval-shaped, film-coated, non-scored tablets containing 40 mg of olmesartan medoxomil. Tablets are debossed with Sankyo on one side and C12, C14, or C15 on the other side of the 5, 20, and 40 mg tablets, respectively. Tablets are supplied as follows: Storage Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature] .
New Drug Application
BENICAR- OLMESARTAN MEDOXOMIL TABLET, FILM COATED BRYANT RANCH PREPACK ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE BENICAR SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR BENICAR. BENICAR (OLMESARTAN MEDOXOMIL) TABLETS, FOR ORAL USE INITIAL U.S. APPROVAL: 2002 WARNING: FETAL TOXICITY _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ When pregnancy is detected, discontinue Benicar as soon as possible (5.1). Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus (5.1). RECENT MAJOR CHANGES Boxed Warning 3/2012 Indications and Usage (1) 2/2012 Contraindications (4) 9/2012 Dosage and Administration: Pediatric Hypertension (6 to 16 years of age) (2.2) 2/2012 Warnings and Precautions: Pregnancy (5.1) 3/2012 Morbidity in Infants (5.2) 2/2012 INDICATIONS AND USAGE Benicar is an angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1). DOSAGE AND ADMINISTRATION INDIC ATIO N STARTING DOSE DOSE RANGE Adult Hypertension (2.1) 20 mg once daily 20 - 40 mg once daily Pediatric Hypertension (6 - 16 years) (2.2) 20 to <35 kg 10 mg once daily ≥35 kg 20 mg once daily 20 to <35 kg 10 - 20 mg once daily ≥35 kg 20 - 40 mg once daily Benicar may be administered with or without food. If blood pressure is not controlled by Benicar alone, a diuretic may be added. Benicar may be administered with other antihypertensive agents. DOSAGE FORMS AND STRENGTHS Tablets: 5 mg, 20 mg, and 40 mg (3). CONTRAINDICATIONS Do not co-administer aliskiren with Benicar in patients with diabetes (4). WARNINGS AND PRECAUTIONS Avoid fetal (in utero) exposure (5.1). Children <1 year of age must not receive Benicar for hypertension (5.2). Observe for signs and symptoms of hypotension in Read the complete document